Boston Scientific May Appeal Fine For 1995 FTC Consent Decree Violation
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific is weighing whether to appeal a $7 mil. civil penalty for failing to supply its Discovery intravascular ultrasound catheters and a patent license to Hewlett-Packard under a 1995 FTC consent decree
You may also be interested in...
Boston Scientific Says Potential FTC Penalties Will Have No Material Impact
Boston Scientific's potential liability for failure to supply Discovery intravascular ultrasound catheters to Hewlett-Packard and provide an IVUS patent license under a 1995 consent order would not result in a "material" financial impact, Boston Scientific says.
Boston Scientific Failed To License Discovery IVUS Catheter To HP - FTC
The ability of Boston Scientific's Discovery intravascular ultrasound catheter to function as a diagnostic and therapeutic tool excluded the product from the firm's consent agreement with the Federal Trade Commission, the firm claims in response to a lawsuit filed Oct. 31 in a Boston federal court.
Hewlett-Packard to enter IVUS catheter market as part of Boston Scientific/FTC deal.
HEWLETT-PACKARD LICENSES BOSTON SCIENTIFIC'S IVUS CATHETERS as part of a consent agreement between Boston Scientific and the Federal Trade Commission allowing Boston Scientific to acquire Scimed and Cardiovascular Imaging Systems. The agreement settles an FTC challenge to the acquisition on the grounds that the deal would be anticompetitive in the intravascular ultrasound field ("The Gray Sheet" Jan. 23, I&W-6).